* Says drug was safe, well-tolerated
* Shares up 50 pct in extended trade
May 24 (Reuters) - Neurocrine Biosciences Inc said a mid-stage study of its drug to treat endometriosis, a gynecological medical condition, met its main and secondary goals, sending shares up over 50 percent after market.
In endometriosis, pieces of the uterine lining grow outside the womb, sometimes sticking to other organs. The condition has no cure and can cause infertility.
The company said the drug, elagolix, showed statistically significant reductions in dysmenorrhea, or pelvic pain during menstruation, and non-menstrual pelvic pain and dyspareunia, or painful intercourse, when compared to placebo.
The study enrolled 137 endometriosis patients, who were given elagolix 150 mg or placebo once daily for two months.
The company said the drug was generally safe and well tolerated. The most common adverse event reported with elagolix was nausea.
Shares of the company were up at $4.10 in extended trade. They closed at $2.73 Monday on Nasdaq.
(Reporting by Jennifer Robin Raj in Bangalore; Editing by Unnikrishnan Nair) Keywords: NEUROCRINE/ (aruna.jennifer@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging:aruna.jennifer.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Shares up 50 pct in extended trade
May 24 (Reuters) - Neurocrine Biosciences Inc said a mid-stage study of its drug to treat endometriosis, a gynecological medical condition, met its main and secondary goals, sending shares up over 50 percent after market.
In endometriosis, pieces of the uterine lining grow outside the womb, sometimes sticking to other organs. The condition has no cure and can cause infertility.
The company said the drug, elagolix, showed statistically significant reductions in dysmenorrhea, or pelvic pain during menstruation, and non-menstrual pelvic pain and dyspareunia, or painful intercourse, when compared to placebo.
The study enrolled 137 endometriosis patients, who were given elagolix 150 mg or placebo once daily for two months.
The company said the drug was generally safe and well tolerated. The most common adverse event reported with elagolix was nausea.
Shares of the company were up at $4.10 in extended trade. They closed at $2.73 Monday on Nasdaq.
(Reporting by Jennifer Robin Raj in Bangalore; Editing by Unnikrishnan Nair) Keywords: NEUROCRINE/ (aruna.jennifer@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging:aruna.jennifer.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.